|
MAGOHB expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.36680000043066E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.88810000004247E-06 |
| Normal-vs-Stage2 |
2.365700E-04 |
| Normal-vs-Stage3 |
6.76189999992971E-07 |
| Normal-vs-Stage4 |
4.27859999652114E-08 |
| Stage1-vs-Stage2 |
9.696200E-01 |
| Stage1-vs-Stage3 |
4.829800E-01 |
| Stage1-vs-Stage4 |
6.173500E-02 |
| Stage2-vs-Stage3 |
5.964400E-01 |
| Stage2-vs-Stage4 |
1.155790E-01 |
| Stage3-vs-Stage4 |
1.943440E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.93200000442317E-08 |
| Normal-vs-AfricanAmerican |
1.344560E-01 |
| Normal-vs-Asian |
1.12890000014687E-07 |
| Caucasian-vs-AfricanAmerican |
6.943600E-02 |
| Caucasian-vs-Asian |
2.280800E-01 |
| AfricanAmerican-vs-Asian |
3.067900E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.66540999999576E-05 |
| Normal-vs-Female |
2.67939999964995E-07 |
| Male-vs-Female |
8.056000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.80109999989998E-07 |
| Normal-vs-Age(41-60Yrs) |
6.5413000016612E-08 |
| Normal-vs-Age(61-80Yrs) |
3.6326000000253E-06 |
| Normal-vs-Age(81-100Yrs) |
4.283200E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.901000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.824800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.431810E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.031400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.153700E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.763400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.809000E-01 |
| Classical-VS-Follicular |
9.525600E-01 |
| Classical-VS-Other |
8.428400E-01 |
| Classical-VS-Normal |
9.89669999951204E-07 |
| Tall-VS-Follicular |
3.393400E-01 |
| Tall-VS-Other |
7.055200E-01 |
| Tall-VS-Normal |
1.7603300000002E-05 |
| Follicular-VS-Other |
8.853200E-01 |
| Follicular-VS-Normal |
8.01910000000072E-05 |
| Other-VS-Normal |
2.356400E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.15180000046256E-07 |
| Normal-vs-N1 |
1.160090E-03 |
| N0-vs-N1 |
5.319200E-01 |
|
|
